| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
JBIO
Jade Biosciences
|
Aug 11, 2026 | BUY |
Strong Buy
+146.6% avg upside
16 analysts
|
$48.00
105.40% Upside
|
+2.6% | · |
|
DMRA
Damora Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
-6.8% avg upside
20 analysts
|
$50.00
60.06% Upside
|
· | · |
|
VRTX
Vertex Pharmaceuticals
|
Aug 11, 2026 | BUY |
Strong Buy
-15.5% avg upside
62 analysts
|
$633.00
19.56% Upside
|
-0.7% | · |
|
BMRN
BioMarin Pharmaceutical
|
Aug 07, 2026 | BUY |
Strong Buy
+35.2% avg upside
52 analysts
|
$104.00
46.87% Upside
|
+7.4% | · |
|
PFE
Pfizer
|
Aug 05, 2026 | BUY |
Buy
+27.4% avg upside
45 analysts
|
$34.00
29.20% Upside
|
+3.8% | · |
|
BNTX
BioNTech SE
|
Aug 04, 2026 | BUY |
Strong Buy
+43.8% avg upside
26 analysts
|
$138.00
47.51% Upside
|
+0.8% | · |
|
NBIX
Neurocrine
|
Jul 30, 2026 | BUY |
Strong Buy
+19.2% avg upside
37 analysts
|
$200.00
26.33% Upside
|
-15.6% | · |
|
GB:0QW0
arGEN X
|
Jul 23, 2026 | BUY |
Strong Buy
-19.1% avg upside
24 analysts
|
— | · | · |
|
IONS
Ionis Pharmaceuticals
|
Jul 15, 2026 | BUY |
Strong Buy
+40.4% avg upside
43 analysts
|
$90.00
57.84% Upside
|
+4.0% | · |
|
ALKS
Alkermes
|
Jul 09, 2026 | BUY |
Strong Buy
-17.2% avg upside
34 analysts
|
$65.00
28.85% Upside
|
-8.7% | · |
|
LLY
Eli Lilly & Co
|
Jul 06, 2026 | BUY |
Strong Buy
-14.8% avg upside
48 analysts
|
$1350.00
10.14% Upside
|
+1.7% | · |
|
SYRE
Spyre Therapeutics
|
Jun 30, 2026 | BUY |
Strong Buy
-9.7% avg upside
23 analysts
|
$98.00
6.30% Downside
|
+14.7% | · |
|
GILD
Gilead Sciences
|
May 22, 2026 | BUY |
Strong Buy
-12.5% avg upside
66 analysts
|
$180.00
31.62% Upside
|
+3.5% | · |
|
CCCC
C4 Therapeutics
|
Apr 30, 2026 | BUY |
Strong Buy
+364.1% avg upside
19 analysts
|
$14.00
253.59% Upside
|
+38.5% | · |
|
REGN
Regeneron
|
Mar 11, 2026 | BUY |
Strong Buy
-1.7% avg upside
58 analysts
|
$890.00
11.79% Upside
|
+3.2% | · |
|
AMGN
Amgen
|
Mar 10, 2026 | HOLD |
Buy
-24.2% avg upside
57 analysts
|
$350.00
16.23% Downside
|
+12.0% | · |
|
ARGX
Argenx Se
|
Feb 19, 2026 | BUY |
Strong Buy
-10.3% avg upside
47 analysts
|
$1008.00
14.88% Upside
|
+1.1% | · |
|
EXEL
Exelixis
|
Dec 11, 2025 | BUY |
Buy
-14.3% avg upside
34 analysts
|
$46.00
10.47% Downside
|
+22.3% | · |
|
CBIO
Crescent Biopharma
|
Dec 05, 2025 | BUY |
Strong Buy
+35.2% avg upside
17 analysts
|
$35.00
113.97% Upside
|
+28.8% | · |
|
ZYME
Zymeworks
|
Nov 17, 2025 | BUY |
Strong Buy
+34.5% avg upside
25 analysts
|
$42.00
69.01% Upside
|
+1.8% | · |
|
ENTA
Enanta Pharmaceuticals
|
Oct 01, 2025 | BUY |
Buy
+143.1% avg upside
17 analysts
|
$20.00
48.57% Upside
|
+26.7% | · |
|
CYTK
Cytokinetics
|
Sep 03, 2025 | BUY |
Strong Buy
+17.8% avg upside
36 analysts
|
$80.00
4.29% Upside
|
+46.9% | · |
|
MDGL
Madrigal Pharmaceuticals
|
Aug 12, 2025 | BUY |
Strong Buy
-6.4% avg upside
33 analysts
|
$502.00
7.28% Downside
|
+49.4% | · |
|
APGE
Apogee Therapeutics
|
Jul 08, 2025 | BUY |
Buy
-7.9% avg upside
19 analysts
|
$96.00
28.76% Downside
|
+266.0% | · |
|
MRK
Merck & Company
|
Jun 18, 2025 | BUY |
Strong Buy
-2.3% avg upside
43 analysts
|
$138.00
3.40% Upside
|
+48.4% | · |
|
ARVN
Arvinas Holding Company
|
May 02, 2025 | HOLD |
Buy
+220.8% avg upside
28 analysts
|
$10.00
12.95% Upside
|
+36.1% | · |
|
BMY
Bristol-Myers Squibb
|
Apr 23, 2025 | BUY |
Buy
-4.3% avg upside
42 analysts
|
$68.00
6.62% Upside
|
+27.7% | · |
|
JAZZ
Jazz Pharmaceuticals
|
Apr 01, 2025 | BUY |
Strong Buy
-5.1% avg upside
35 analysts
|
$183.00
27.28% Downside
|
+50.6% | · |
|
ZNTL
Zentalis Pharmaceuticals
|
Jan 29, 2025 | HOLD |
Buy
+228.4% avg upside
18 analysts
|
$2.50
40.05% Downside
|
+32.8% | · |
|
RLAY
Relay Therapeutics
|
Dec 11, 2024 | BUY |
Strong Buy
+8.5% avg upside
21 analysts
|
$17.00
14.84% Downside
|
+56.4% | · |
|
ACRV
Acrivon Therapeutics, Inc.
|
Dec 12, 2022 | BUY |
Strong Buy
+734.8% avg upside
13 analysts
|
$17.00
882.70% Upside
|
-60.1% | · |
|
VTRS
Viatris
|
Feb 26, 2021 | HOLD |
Buy
+45.6% avg upside
21 analysts
|
— | +1.0% | · |
|
TSE:BHC
Bausch Health Companies
|
Jan 29, 2020 | HOLD |
Buy
+572.9% avg upside
29 analysts
|
— | -15.2% | · |
|
TEVA
Teva Pharmaceutical
|
Jul 19, 2019 | HOLD |
Buy
-17.9% avg upside
39 analysts
|
$9.00
75.42% Downside
|
+56.3% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.